KittisakJirasittichai / iStockphoto.com
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports.
Striking the perfect balance between incentivising innovation in drug development and widening access to medicines through generic competition is perhaps an unobtainable aim, but it’s an ideal that legislators and regulators must strive towards.
In 2016, in its “Resolution in the Single Market Strategy”, the European Parliament urged the European Commission to boost competition in the generic and biosimilar drugs market—without undermining the market exclusivity granted to IP owners—by 2019.
In response, in May this year, the Commission announced its plan to introduce a manufacturing waiver in relation to Regulation 469/2009, which governs the grant and scope of supplementary protection certificates (SPCs).
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
European Commission, supplementary protection certificate, patent, waiver, safeguard, market exclusivity, generic manufacturing, drug competition